Healthcare · Biotechnology
Price
$2.66
Market Cap
$167.5M
Employees
62
Beta
-0.23
Avg Volume
310,265
CEO
Barry D. Quart
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to discovering and advancing immune modulators. Its primary objective is to develop treatments for serious autoimmune diseases and various inflammatory conditions. The company's lead investigational therapy is CBP-201, an anti-interleukin-4 receptor alpha antibody. This candidate is currently in Phase IIb clinical trials, targeting inflammatory allergic diseases such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Additionally, Connect Biopharma's pipeline includes CBP-307, a small molecule designed to modulate sphingosine 1-phosphate receptor 1. This receptor plays a crucial role in regulating T cell movement from lymph nodes into the bloodstream. CBP-307 is in Phase II development for treating autoimmune-related inflammatory disorders. Another preclinical-stage asset, CBP-174, is an orally administered small molecule histamine receptor 3 antagonist, being investigated for chronic pruritus (itch) associated with skin inflammation. The portfolio also features CBP-233, a humanized antibody in preclinical development that targets interleukin-33, a cytokine recognized for its involvement in T helper 2 inflammation. Established in 2012, the company maintains its headquarters in Taicang, China.
Runs with full report
Price Overview
Last updated: Jul 10, 2026 1:47am (just now)
Current data · timestamped when a report runs
$2.66
Change · Jul 10
+0.44 (+19.82%)
Day Range
$2.27 – $2.78
52-Week Range
$1.09 – $3.82
50-Day MA
$2.30
200-Day MA
$2.35
Volume
2,463,644.00
Analyst Price Targets
Low
$4.00
Consensus
$6.40
High
$8.00
(7 analysts)
Share Structure
Outstanding
62,963,853.00
Float
15,434,718.00
Free Float
24.5%
Low free float
— 24.5% of shares trade freely, ~75.5% held by insiders/institutions
Below average liquidity. Large orders can move the price significantly. Insiders or strategic holders control the majority — watch for lockup expirations or secondary offerings.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-2.66
Stock Price: $2.66
EPS (Diluted): -1.00
EPS (Diluted): -1.00
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
3.74
Stock Price: $2.66
Total Equity: $41.98M
Shares: 55,660,000
Total Equity: $41.98M
Shares: 55,660,000
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-4.71
Market Cap: $167.48M
Total Debt: $0.00
Cash: $38.35M
EBITDA: -$54.58M
Total Debt: $0.00
Cash: $38.35M
EBITDA: -$54.58M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$119.3M
Market Cap: $167.48M
Total Debt: $0.00
Cash: $38.35M
Total Debt: $0.00
Cash: $38.35M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
2,452.52
Stock Price: $2.66
Revenue: $64,000
Shares: 55,660,000
Revenue: $64,000
Shares: 55,660,000
EV/Sales (Total value vs revenue — works when P/E can't)
API1,864.16
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
100.0%
Gross Profit: $64,000
Revenue: $64,000
Revenue: $64,000
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
-90,740.6%
Operating Income: -$58.07M
Revenue: $64,000
Revenue: $64,000
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
-86,687.5%
Net Income: -$55.48M
Revenue: $64,000
Revenue: $64,000
ROE (Profit from shareholder equity)
APINet Income / Total Equity
-49.4%
Net Income: -$55.48M
Total Equity: $41.98M
Total Equity: $41.98M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-67.7%
Operating Income: -$58.07M
Tax Rate: -0.4%
Equity: $41.98M
Total Debt: $0.00
Cash: $38.35M
Tax Rate: -0.4%
Equity: $41.98M
Total Debt: $0.00
Cash: $38.35M
Zero debt — invested capital = equity minus cash (very efficient)
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
3.74
Current Assets: $50.93M
Current Liabilities: $13.61M
Current Liabilities: $13.61M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.00
Short-Term Debt: $0.00
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $41.98M
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $41.98M
Zero debt — this company carries no debt obligations. Strongest possible score.
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$0.00
Revenue: $64,000
Shares: 55,660,000
Shares: 55,660,000
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$0.75
Total Equity: $41.98M
Shares: 55,660,000
Shares: 55,660,000
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-0.93
Operating CF: -$51.21M
CapEx: -$434,000
Shares: 55,660,000
CapEx: -$434,000
Shares: 55,660,000
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $2.66
Stock Price: $2.66
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$55.48M
Net Income: -$55.48M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares CNTB against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jul 10, 2026 1:47am (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $26.0M | $64,000 |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $26.0M | $64,000 |
| Operating Expenses | $98.1M | $119.3M | $69.1M | $48.5M | $58.1M |
| Operating Income | -$98.1M | -$119.3M | -$69.1M | -$22.5M | -$58.1M |
| Net Income | -$202.3M | -$118.1M | -$62.1M | -$15.6M | -$55.5M |
| EBITDA | -$201.4M | -$116.7M | -$61.3M | -$14.7M | -$54.6M |
| EPS | $-25.00 | $-14.50 | $-1.08 | $-0.28 | $-1.00 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jul 10, 2026 1:47am (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $267.7M | $79.0M | $105.7M | $78.2M | $38.3M |
| Total Current Assets | $275.1M | $155.8M | $122.6M | $97.0M | $50.9M |
| Total Assets | $291.1M | $174.0M | $127.4M | $101.3M | $56.1M |
| Current Liabilities | $18.0M | $15.6M | $25.3M | $8.5M | $13.6M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $18.8M | $16.5M | $25.9M | $9.1M | $14.1M |
| Total Equity | $272.3M | $157.5M | $101.5M | $92.2M | $42.0M |
| Retained Earnings | -$361.8M | -$479.8M | -$329.7M | -$345.4M | -$400.8M |
Cash Flow (Annual)
Last updated: Jul 10, 2026 1:47am (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$85.6M | -$99.3M | -$47.9M | -$23.6M | -$51.2M |
| Capital Expenditure | -$7.5M | -$4.3M | $-294,000 | $-750,000 | $-434,000 |
| Free Cash Flow | -$93.0M | -$103.6M | -$48.2M | -$24.4M | -$51.6M |
| Acquisitions (net) | $47,735 | $79,161 | $2.9M | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $-566,000 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $109.4M | -$168.9M | $27.0M | -$27.4M | -$39.9M |
Analyst Estimates (Annual)
Last updated: Jul 10, 2026 1:47am (just now)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$9.0M $1.1M – $17.0M
|
$16.6M $16.3M – $16.8M
|
$35.2M $2.2M – $98.8M
|
$74.4M $4.7M – $208.6M
|
| EBITDA |
$2.6M $306,578 – $4.9M
|
$4.8M $4.7M – $4.8M
|
$10.1M $632,952 – $28.3M
|
$21.3M $1.3M – $59.8M
|
| Net Income |
-$53.6M -$59.5M – -$47.8M
|
-$47.9M -$62.9M – -$32.9M
|
-$43.0M -$144.1M – $9.4M
|
-$29.8M -$99.7M – $6.5M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jul 10, 2026 1:47am (just now)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | — | — | — | -99.8% |
| Gross Profit Growth | — | — | — | -99.8% |
| Operating Income Growth | -21.6% | +42.1% | +67.5% | -158.7% |
| Net Income Growth | +41.6% | +47.4% | +74.8% | -255.0% |
| EBITDA Growth | +42.0% | +47.5% | +75.9% | -270.2% |
Insider Trading (Recent)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-06-30 | Xanthopoulos Kleanthis Gabriel | A-Award | 3,738.00 | $0.00 | $0 |
| 2026-06-30 | LIU JEAN I | A-Award | 6,718.00 | $0.00 | $0 |
| 2026-05-29 | Huang James | P-Purchase | 150,000.00 | $2.48 | $371,610 |
| 2026-03-31 | Xanthopoulos Kleanthis Gabriel | A-Award | 2,816.00 | $0.00 | $0 |
| 2026-03-31 | LIU JEAN I | A-Award | 5,061.00 | $0.00 | $0 |
| 2026-03-31 | Huang James | P-Purchase | 1,160,000.00 | $3.45 | $4.0M |
| 2026-03-18 | Huang James | 0.00 | $0.00 | $0 | |
| 2026-03-16 | Szekeres David Leslie | 0.00 | $0.00 | $0 | |
| 2026-03-16 | Szekeres David Leslie | 1,772,489.00 | $1.77 | $3.1M | |
| 2026-03-16 | Szekeres David Leslie | 409,355.00 | $0.97 | $397,074 | |
| 2026-03-16 | Szekeres David Leslie | 400,000.00 | $2.69 | $1.1M | |
| 2026-03-16 | Quart Barry D | 0.00 | $0.00 | $0 | |
| 2026-03-16 | Quart Barry D | 0.00 | $0.00 | $0 | |
| 2026-03-16 | Quart Barry D | 2,658,734.00 | $1.77 | $4.7M | |
| 2026-03-16 | Quart Barry D | 432,392.00 | $0.97 | $419,420 | |
| 2026-03-16 | Quart Barry D | 700,000.00 | $2.69 | $1.9M | |
| 2026-03-16 | Peraza Lisa | 0.00 | $0.00 | $0 | |
| 2026-03-16 | Peraza Lisa | 55,318.00 | $0.97 | $53,658 | |
| 2026-03-16 | Peraza Lisa | 400,000.00 | $1.15 | $460,000 | |
| 2026-03-16 | Peraza Lisa | 40,000.00 | $1.14 | $45,600 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for CNTB — it's generated by the pipeline (
market-narrative step).
No community reviews yet for CNTB.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.397 · fd27f02b · 2026-07-09 18:28:55